Vancomycin Clearance with High-Flux Dialysis Membranes

Kuchle C. Fricke H. Held E. et al. High-flux hemodialysis postpones clinical manifestations of dialysis-related amyloidosis. Am J Clin Nephrol 1996; 16: 16:484–8.

Acchiardo S.R. High-flux hemodialysis. In: Hemodialysis. Highefficiency treatments ( Bosh J.P. Stein J.H. eds.). Contemporary Issues in Nephrology 1993, 27: 105–17.

Rockel A. , Hertel J. , Fiegel P. Permeability and secondary membrane formation of a high flux polysulfone hemofilter. Kid Int 1986; 30: 429.

Fekety R. . Vancomycin and teichoplanin. In: Principles and Practice of Infectious Diseases ( Mandell G.L. , Bennett J.E. , Dolin R. , eds.). New York, Churchill Livingstone, 1995; 346–50.

Matzke G.R. , Vancomycin. In: Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring ( Evans W.E. , Schentag J.J. , Jusko W.J. , eds.). Applied Therapeutics, Vancouver, 1992; 15-1–15-31.

Bastani B. , Spyker D.A. , Minocha A. In vivo comparison of three different hemodialysis membranes for vancomycin clearance: Cuprophane, cellulose acetate and polyacrylonitrile. Dial Transplant 1988; 17: 527–43.

Lanese Dm , Alfrey P.S. , Molitoris B.A. . Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 1989; 35: 1409–12.

Torras J. , Cao C. , Rivas M.C. Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile. Clin Nephrol 1991; 36: 35–41.

Quale J.M. , O'Halloran J.J. , DeVincenzo N. Removal of vancomycin by high-flux hemodialysis membranes. Antimicrobial Agents Chemother 1992; 36: 1424–6.

DeSoi C.A. , Sahm D.F. , Umans J.G. . Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis 1992; 20: 354–60.

Pollard T.A. , Lampasona V. , Akkerman S. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kid Int 1994; 45: 232–7.

Touchette M.A. , Patel R.V. , Anandan J.V. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis 1995; 26: 469–74.

Welage L.S. , Mason N.A. , Hoffman E.J. Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics. J Am Soc Nephrol 1995; 6: 1284–90.

Barth R.H. , DeVincenzo N. . Use of vancomycin in high-flux hemodialysis: Experience with 130 courses of therapy. Kidney Int 1996; 50: 929–36.

Matzke G.R. , O'Connell M.B. , Collins A.J. Disposition of vancomycin during hemofiltration. Clin Pharmacol Ther 1986; 40: 425–30.

Bellomo R. , Ernest D. , Parkin G. Clearance of vancomycin during continuous arteriovenous hémodiafiltration. Crit Care Med 1990; 18: 181–3.

Bohler J. , Reetze-Bonorden P. , Schollmeyer P.J. Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes. Eur J Clin Pharmacol 1992; 42: 635–40.

Scott M.K. , Macias W.L. , Mueller B.A. Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy 1997; 17: 256–62.

Hu M.W. , Anne L. , Forni T. , Gottwald K. . Measurement of vancomycin in renally impaired patient samples using a new high-performance liquid chromatography method with vitamin B12 internal standard: Comparison of high-performance liquid chromatography, EMIT, and fluorescence polarization immunoassay methods. Ther Drug Monit 1990; 12: 562–9.

Follin S.L. , Mueller B.A. , Scott M.K. , Carfagna M.A. , and Kraus M.A. . Falsely elevated serum vancomycin concentrations in hemodialysis patients. Am J Kidney Dis 1996; 27: 67–74.

Moellering RC Jr. . Editorial: Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994; 18: 544–6.

Saunders N.J. . Why monitor peak vancomycin concentrations? Lancet 1994; 344: 1748–50.

Ackerman B.H. . Clinical value of monitoring serum vancomycin concentrations. Clin Infect Dis 1994; 19: 1180–1.

Goldstein E. , Bartholomew W.R. , Vickers M.K. , Parr T. . Are serum levels of vancomycin useful in the first week of therapy? Missouri Medicine 1995; 92: 596–9.

Levine D.P. , Fromm B.S. , Reddy B.R. . Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674–80.

Viladrich P.F. , Gudiol F. , Linares J. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991; 35: 2467–72.

Ackerman B.H. , Vannier A.M. , Eudy E.B. . Analysis of vancomycin time-kill studies with Staphylococcus species by using curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992; 36: 1766–9.

Schaad U.B. , McCracken G.E. , Nelson J.D. . Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96: 119–26.

Lisby-Sutch S.M. , Nahata M.C. . Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988; 35: 637–42.